お知らせ • Sep 21
bioAffinity Technologies, Inc. Announces Board Changes
Roby P. Joyce, MD, age 75, was appointed to serve on the bioAffinity Technologies, Inc.’s Board of Directors on September 18, 2023, contingent upon and effective as of the consummation of the Acquisition. The Company also entered into the Joyce Employment Agreement, for a term of three years, pursuant to which he serves as the Medical Director and Laboratory Director of PPLS at a base salary of $333,333.34 per year. He is also the owner of Village Oaks Pathology, the medical professional association whose pathologists work with PPLS. Dr. Joyce is board-certified in anatomic and clinical pathology by the College of American Pathologists and is a Diplomat in the American Board of Pathology. He is also board-certified in neurology by the American Academy of Neurology and is a Diplomat in the American Board of Psychiatry and Neurology. Dr. Joyce founded Village Oaks Pathology in 2007, where he created and operated a successful pathology laboratory that developed CyPath® Lung as a laboratory developed test (“LDT”). In addition, he has served in various capacities at Northeast Methodist Hospital in San Antonio, including Chairman of the Board of Trustees and Chief of Staff of the Methodist Healthcare System. Throughout a career in pathology that spans more than 40 years, he has been a highly regarded speaker at medical and scientific conferences, has served in leadership roles on dozens of professional organizations and committees, and has served as lead or co-author of numerous scientific articles. Dr. Joyce received his medical degree from Louisiana State University, where he also received a BS in zoology. He performed his internship at Fitzsimons Army Medical Center in Denver, his residency in neurology at the Letterman Army Medical Center at the University of California Moffett Hospital in San Francisco, and his residency in pathology at Brooke Army Medical Center in San Antonio. Xavier Reveles, age 54, who has served as the Company’s Vice President of Operations as an employee at will since September 2022, was appointed to serve as the Company’s Chief Operating Officer on September 18, 2023, contingent upon and effective as of the consummation of the Acquisition. In connection with such appointment, Mr. Reveles’ annual base salary was increased from $150,000 to $175,000, effective September 18, 2023. The Company does not have an employment agreement with Mr. Reveles, but the Company intends to enter into an employment agreement with him, the form, terms and conditions of the which shall be substantially the same as the Company’s current executive officers other than salary and title, pursuant to which he will earn his increased annual base salary of $175,000 per year. He has 30 years of experience as a clinical cytogeneticist skilled in the design/concept and management of CAP CLIA clinical laboratories, coding, CPT reimbursement valuations, and the development of LDTs. Mr. Reveles is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics. He joined bioAffinity as Director of Operations in 2017. Prior to joining bioAffinity, Mr. Reveles created the Oncopath Laboratory – START Cancer Center (“Oncopath”) in San Antonio, Texas, and served as Laboratory Director. During his tenure at Oncopath, he commercialized eight LDTs, including bringing to market a proprietary cancer specific gene oligo array he designed for the deletions and amplifications of specific oncogenes for solid tumors. As the Director of the Cytogenetics Laboratory at UT Health San Antonio, Mr. Reveles’ research included molecular evaluation of disease progression in prostate, breast and ovarian cancer, schizophrenia, diabetes and other constitutional genetic syndromes. He was a lecturer and instructor for the UT Health Graduate, Medical, and Allied Health Schools and the director of the NCI San Antonio Cancer Institute (SACI) Genetics and Cytogenetics Core facility. After leaving academia, Mr. Reveles was a genomic specialist for CombiMatrix Diagnostics, Irvine, CA, a diagnostic biotech company where he validated pre-natal, post-natal, and cancer gene arrays for commercialization as LDTs. Mr. Reveles is (co)author of 20 publications and six abstracts in peer-reviewed journals and is a member of the Association for Molecular Pathology.